338 related articles for article (PubMed ID: 38672566)
1. Emerging Therapies for Glioblastoma.
Rios SA; Oyervides S; Uribe D; Reyes AM; Fanniel V; Vazquez J; Keniry M
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672566
[TBL] [Abstract][Full Text] [Related]
2. Targeting protein kinase CK2 suppresses prosurvival signaling pathways and growth of glioblastoma.
Zheng Y; McFarland BC; Drygin D; Yu H; Bellis SL; Kim H; Bredel M; Benveniste EN
Clin Cancer Res; 2013 Dec; 19(23):6484-94. PubMed ID: 24036851
[TBL] [Abstract][Full Text] [Related]
3. Novel Therapies in Glioblastoma Treatment: Review of Glioblastoma; Current Treatment Options; and Novel Oncolytic Viral Therapies.
Shah S
Med Sci (Basel); 2023 Dec; 12(1):. PubMed ID: 38249077
[TBL] [Abstract][Full Text] [Related]
4. Ruxolitinib enhances cytotoxic and apoptotic effects of temozolomide on glioblastoma cells by regulating WNT signaling pathway-related genes.
Goker Bagca B; Ozates NP; Biray Avci C
Med Oncol; 2022 Dec; 40(1):37. PubMed ID: 36460932
[TBL] [Abstract][Full Text] [Related]
5. Emerging therapies for glioblastoma.
Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
[TBL] [Abstract][Full Text] [Related]
6. Congress of neurological surgeons systematic review and evidence-based guidelines update on the role of emerging developments in the management of newly diagnosed glioblastoma.
Farrell C; Shi W; Bodman A; Olson JJ
J Neurooncol; 2020 Nov; 150(2):269-359. PubMed ID: 33215345
[TBL] [Abstract][Full Text] [Related]
7. Oncolytic Viruses for Malignant Glioma: On the Verge of Success?
Suryawanshi YR; Schulze AJ
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372501
[TBL] [Abstract][Full Text] [Related]
8. Current Opportunities for Targeting Dysregulated Neurodevelopmental Signaling Pathways in Glioblastoma.
Drakulic D; Schwirtlich M; Petrovic I; Mojsin M; Milivojevic M; Kovacevic-Grujicic N; Stevanovic M
Cells; 2022 Aug; 11(16):. PubMed ID: 36010607
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy of glioblastoma: Recent advances and future prospects.
Yuan B; Wang G; Tang X; Tong A; Zhou L
Hum Vaccin Immunother; 2022 Nov; 18(5):2055417. PubMed ID: 35344682
[TBL] [Abstract][Full Text] [Related]
10. Emerging Recombinant Oncolytic Poliovirus Therapies Against Malignant Glioma: A Review.
Dighe OR; Korde P; Bisen YT; Iratwar S; Kesharwani A; Vardhan S; Singh A
Cureus; 2023 Jan; 15(1):e34028. PubMed ID: 36814733
[TBL] [Abstract][Full Text] [Related]
11. The need for paradigm shift: prognostic significance and implications of standard therapy-related systemic immunosuppression in glioblastoma for immunotherapy and oncolytic virotherapy.
Stepanenko AA; Sosnovtseva AO; Valikhov MP; Chernysheva AA; Abramova OV; Naumenko VA; Chekhonin VP
Front Immunol; 2024; 15():1326757. PubMed ID: 38390330
[TBL] [Abstract][Full Text] [Related]
12. Oncolytic virus-mediated manipulation of DNA damage responses: synergy with chemotherapy in killing glioblastoma stem cells.
Kanai R; Rabkin SD; Yip S; Sgubin D; Zaupa CM; Hirose Y; Louis DN; Wakimoto H; Martuza RL
J Natl Cancer Inst; 2012 Jan; 104(1):42-55. PubMed ID: 22173583
[TBL] [Abstract][Full Text] [Related]
13. Crosstalk between PI3K/AKT/mTOR and WNT/β-Catenin signaling in GBM - Could combination therapy checkmate the collusion?
Daisy Precilla S; Biswas I; Kuduvalli SS; Anitha TS
Cell Signal; 2022 Jul; 95():110350. PubMed ID: 35525406
[TBL] [Abstract][Full Text] [Related]
14. Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy.
Dhungel L; Rowsey ME; Harris C; Raucher D
Molecules; 2024 Feb; 29(4):. PubMed ID: 38398592
[TBL] [Abstract][Full Text] [Related]
15. Oncolytic Viral Therapy for Malignant Glioma and Their Application in Clinical Practice.
Shoaf ML; Desjardins A
Neurotherapeutics; 2022 Oct; 19(6):1818-1831. PubMed ID: 35674873
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy.
Qi Z; Long X; Liu J; Cheng P
Front Cell Neurosci; 2022; 16():819363. PubMed ID: 36159398
[TBL] [Abstract][Full Text] [Related]
17. Expression of STAT3 and hypoxia markers in long-term surviving malignant glioma patients.
Dvorakova K; Skarkova V; Vitovcova B; Soukup J; Vosmikova H; Pleskacova Z; Skarka A; Bartos MC; Krupa P; Kasparova P; Petera J; Rudolf E
BMC Cancer; 2024 Apr; 24(1):509. PubMed ID: 38654280
[TBL] [Abstract][Full Text] [Related]
18. Recent Developments in Glioblastoma Therapy: Oncolytic Viruses and Emerging Future Strategies.
Hamad A; Yusubalieva GM; Baklaushev VP; Chumakov PM; Lipatova AV
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851761
[TBL] [Abstract][Full Text] [Related]
19. Gene therapeutics: the future of brain tumor therapy?
Cutter JL; Kurozumi K; Chiocca EA; Kaur B
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1053-64. PubMed ID: 16831077
[TBL] [Abstract][Full Text] [Related]
20. Obstacles to Glioblastoma Treatment Two Decades after Temozolomide.
Cruz JVR; Batista C; Afonso BH; Alexandre-Moreira MS; Dubois LG; Pontes B; Moura Neto V; Mendes FA
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
